Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma by Cho, M et al.
Human renal cell carcinoma (RCC) cells frequently express a
tumour-associated antigen, MN, recognized by mouse monoclonal
antibody G250 (Oosterwijk et al, 1986; Grabmaier et al, 2000).
This antigen is a plasma membrane glycoprotein with an apparent
molecular weight of 54/58 kDa (Pastorek et al, 1994), detectable
in several types of malignancies as well as RCCs, e.g. cervical and
ovarian (Liao et al, 1996), colorectal (Saarnio et al, 1998),
oesophageal (Turner et al, 1997) and bladder cancers (Uemura 
et al, 1996). MN expression in normal tissues is restricted to the
alimentary tract (Oosterwijk et al, 1986), suggesting a possible
role in oncogenesis. Although MN may be useful as a target mole-
cule for immunotherapy of RCCs (Uemura et al, 1999) and as a
biomarker for kidney (Mckiernan et al, 1997), cervical (Liao et al,
1996), and colorectal cancers (Saarnio et al, 1998), its function and
mechanisims of activation of the MN coding gene, MN/CA9, in
malignancies remains poorly understood. The few investigations
that have been conducted have suggested possible roles of VHL
(Ivanov et al, 1998), p53 (Kaluzova et al, 2000) and DNA
hypomethylation (Cho et al, 2000) in malignancies. 
Inverse correlations are frequently observed between DNA
methylation and gene transcription in both normal and malignant
cells. CpG methylation in regulatory regions can influence tran-
scription directly by interfering with the binding of positively or
negatively acting transcription factors or indirectly by the forma-
tion of inactive chromatin (Zingg et al, 1997). DNA hypomethyla-
tion is associated with overexpression or activation of some genes
linked to cancer, e.g. c-myc in hepatocellular carcinomas
(Tsujiuchi et al, 1999), bcl-2 in chronic lymphocytic leukaemias
(Hanada et al, 1993), MAGE-1 in melanomas (De Smet et al,
1996), and MDR1 in acute myeloid leukaemias (Nakayama et al,
1998). The expression of some tissue-specific genes, such as these
for transglutaminase (Lu and Davies, 1997), L-histidine decar-
boxylase (Kuramasu et al, 1998) and globin (Busslinger et al,
1983) is correlated inversely with the methylation status of the
promoter region. The fact that expression of MN/CA9 is tissue
specific and cancer related, suggests a possible role for DNA
hypomethylation in its activation. The region immediately
upstream of the transcription start site of MN/CA9 has no TATA
box and no CpG island and contains consensus sequences for tran-
scription factors such as AP1, AP2, and p53 (Opavsky et al, 1996). 
Our previous data demonstrated that MN/CA9 activation is asso-
ciated with hypomethylation of the promoter region in human
RCC cell lines (Cho et al, 2000). It is interesting for us to reveal
whether such a correlation would be observed in vivo and whether
epigenetic change of particular CpG sites would affect MN/CA9
transcription. 
In the present study, we investigated the correlation between
MN/CA9 expression and methylation status of MN/CA9 promoter
using human RCC tissue materials and examined the effect of
DNA methylation on the promoter activity of MN/CA9. 
MATERIALS AND METHODS 
RT-PCR analyses 
Tissue specimens were obtained from 13 patients with RCCs who
underwent radical operations in Nara Medical University Hospital.
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and small pieces of tumour or normal kidney tissue were frozen in
liquid nitrogen and stored at –80˚C. The remainder of each kidney
was submitted for pathological examination. Histopathological
diagnosis was conducted by one pathologist (NK). Total RNAs
were isolated from frozen tissue samples by using an ISOGEN kit
(NIPPON GENE, Toyama, Japan). RT-PCR was performed to esti-
mate  MN/CA9 expression as described previously (Cho et al,
2000). PCR primers were designed to cover the 495-bp region
from exon 1 to 3 of MN/CA9 (sense: 5′ -ACTGCTGCTTCTG-
ATGCCTGT-3′ , antisense: 5′ -TCCCGCCGCTCCCAGAACT-3′ ).
The amplification was achieved with 30 cycles, each consisting of
denaturation (95˚C, 2 min), annealing (68˚C, 2 min), and exten-
sion (72˚C, 1 min). The PCR products were electrophoresed on
1% agarose gels and stained with ethidium bromide. β -actin
cDNAs were amplified as the internal control. 
Bisulfite genomic sequencing protocol 
Genomic DNAs were extracted from tissue samples and treated
with sodium metabisulfite as described previously (Cho et al,
2000). The 5′ region (nt–142 to +267) of the bisulfite-modified
MN/CA9 gene was amplified using nested PCR. First PCR ampli-
fication was performed in 20 µ l reaction mixtures containing 3 µ l
of bisulfite-treated genomic DNA, 10 mM Tris-HCl, pH 8.3, 50
mM KCl, 1.5 mM MgCl2, 0.5 µ M each primer, 0.2 mM dNTPs,
and 0.5 U Taq DNA polymerase (AmpliTaq Gold, Perkinelmer)
under the following conditions: 94˚C for 1 min, 50˚C for 2 min,
and 72˚C for 3 min for 5 cycles and 94˚C for 0.5 min, 50˚C for
1.5 min, and 72˚C for 1.5 min for 30 cycles (sense: 5′ -
TTGGTATGGGGGAGAGGGTA-3′ , antisense: 5′ -GGATTTATT-
TAGAGAGGAGG-3′ ). Nested PCR amplification was similarly
carried out using 0.5 µ L of the first PCR reaction mixture as
a template (sense: 5′ -GAGAGGGTATAGGGTTAGAT-3′ , anti-
sense: 5′ -AGTGAAGAGGAGGATTTATTTAG-3′ ). Agarose gel-
purified PCR products were directly sequenced using a sequencing
kit (Sequencing PRO, TOYOBO, Osaka, Japan) with primers radi-
olabelled with [γ -32P] ATP. Methylation status was investigated at
6 CpG sites in the MN/CA9 promoter region. 
Plasmid construction 
The MN –1246 to + 42 fragment from a cosmid clone was
amplified by PCR using adaptor primers (sense: 5′ -CGGGGTAC-
CTAAAGCAGAATTC, antisense: 5′ -CCGCTCGAGATGCG-
GCTGACT). PCR fragments were subcloned into Kpn I and Xho I
sites of pGL3-Basic vector (Promega), and nested deletions were
made by the exonuclease III and mung-bean nuclease method
(Henikoff, 1987). Deletion mutants containing the minimal
promoter region of MN/CA9 (–158 to +42) were used in the
present study (Kaluz et al, 1999). 
Cell culture, transfection and luciferase assay 
Human RCC cell lines, SK-RC-10, SK-RC-12, SK-RC-14 and
SK-RC-44, were grown in RPMI 1640 medium supplemented
with 10% fetal calf serum. Each cell line was plated at 2   105 cells
in 35 mm culture dishes and 50–80% confluent cells were trans-
fected with 1 µ g of reporter constructs and 3 µ l of FuGENE™ 6
reagent (Roche, USA). The cells were then harvested 24 h post-
transfection and luciferase quantities were assayed with a
luciferase assay kit (Promega) using a TR717 Microplate
Luminometer (PE Biosystems, Tokyo, Japan). All transfections
were carried out in 2 independent experiments and in triplicate.
Luciferase quantities were displayed as percentage value of those
of positive control vectors with an enhancer and promoter of SV40
(pGL3-Control Vector, Promega). Reporter vectors expressing
EGFP (pIRES2-EGFP Vector, CLONTECH) were used for
examination of transfection efficiency. 
In vitro DNA methylation 
Bacterial methylases Sss I and Hha I were used to methylate the
MN/CA9 promoter/luciferase reporter constructs. Plasmid DNA
was incubated with 3 units of Sss I or Hha I methylase per µ g of
DNA in 50 mM Tris-HCL, pH 7.5/10 mM EDTA/80 mM S-
adenosylmethionine/5 mM 2-mercaptoethanol. All methylation
reactions were carried out at 37˚C overnight. To test the samples
for complete methylation, the DNA was digested with Sss I or
Hha I restriction endonucleases and analyzed by agarose gel elec-
trophoresis. 
RESULTS 
MN/CA9 expression in RCC tissues 
Table 1 summarizes histopathological findings and the results of
MN/CA9 expression of 13 RCC tissue samples. The distribution of
pathological stage, grade and morphological type was as follows:
pT1a in 3, pT1b in 4, pT2 in 2, pT3a in 2, pT3b in 1 and pT4 in 1,
and G1 in 2, G2 in 9 and G3 in 2, and clear cell in 7, clear/granular
cell in 4, granular cell in 1 and spindle cell in 1. MN/CA9 expres-
sion was evaluated by RT-PCR and observed in 10 of 13 RCCs
(77%). Correlations between MN/CA9 expression and tumour
stage and grade were not observed. 
Methylation status of the MN/CA9 promoter region 
The methylation status of 6 CpG sites in the MN/CA9 promoter
region was examined in RCCs and non-cancerous kidney tissues.
A total of 9 of 13 RCCs showed partial methylation of the CpG
at –74 bp, while the other 4 showed complete methylation (Table
2). Partial methylation indicates the existence of both methy-
lated and unmethylated CpGs. The CpG at –19 bp was not deter-
mined as to methylation status because of stacking of
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Table 1 Pathological characteristics and MN/CA9 expression in human
RCC 
Sample Stage Grade Morphological type MN/CA9 expression 
RCC 1 pT1b 2 Clear + 
RCC 2 pT1b 2 Clear/granular + 
RCC 3 pT1a 2 Clear/granular + 
RCC 4 pT3a 2 Clear/granular + 
RCC 5 pT4 3 Spindle – 
RCC 6 pT1b 2 Clear + 
RCC 7 pT3b 3 Granular – 
RCC 8 pT1b 2 Clear + 
RCC 9 pT2 1 Clear/granular – 
RCC 10 pT1a 2 Clear + 
RCC 11 pT3a 2 Clear + 
RCC 12 pT2 1 Clear + 
RCC 13 pT1a 2 Clear + sequencing gels. Other CpGs less frequently showed partial
methylation in RCCs (3 out of 13). All CpGs except –19 bp were
completely methylated in non-cancerous kidney tissues. Figure 1
shows bisulfite genomic sequences around the CpG at –74 bp in
tissue samples. 
Correlation between MN/CA9 expression and
methylation status of the MN/CA9 promoter region 
MN/CA9 expression was strongly correlated with partial methyla-
tion (partial hypomethylation) of the CpG at –74 bp. Out of 10
MN/CA9-positive RCCs (90%) showed hypomethylation, while
this was the case in none of the MN/CA9-negative RCCs and 
non-cancerous kidney tissues (0%). 
Differences of MN/CA9 promoter activities among
4 human RCC cell lines 
Our previous study demonstrated that MN/CA9 was expressed in
SK-RC-10 and SK-RC-44, while not expressed in SK-RC-12 and
SK-RC-14 (Cho et al, 2000). Levels of luciferase activity
were 21% in SK-RC-10 cells, 13.7% in SK-RC-44 cells, 1.5% in
SK-RC-12 cells and 0.6% in SK-RC-14 cells (Figure 2). 
Effects of in vitro CpG methylation on promoter activity 
To examine whether CpG methylation of the MN/CA9 promoter
might influence the promoter activity, the MN/CA9 promoter/
luciferase reporter constructs were treated with Sss I methylase,
acting all CpG sites, or with Hha I methylase, recognizing GCGC
sequences with or without methyl donors. The MN/CA9 promoter
(–158 to + 42) contains only one GCGC sequence, corresponding
to the CpG at –74 bp. Methylated and mock-methylated constructs
were transfected into SK-RC-44 cells. Mock-methylated con-
structs with Sss I and Hha I showed luciferase activity at levels of
14.2% and 12.8%, respectively, however in neither enzyme did
methylated constructs exhibit luciferase activity (Figure 3). 
DISSCUSION 
The present study revealed that in human RCC tissues,
hypomethylation of the CpG dinucleotide at –74 bp is strongly
correlated with MN/CA9 expression, suggesting that hypomethyla-
tion of this site may play an important role in upregulation of this
marker in RCC tissues. MN/CA9 expression did not correlate with
tumour stage or grade. These findings are not consistent with our
previous study (Uemura et al, 1999). The difference seems to be
due to small sample size of the present study. Partial hypomethyla-
tion at this site was frequently observed in RCCs with clear cell
components, while it was not in RCCs without such components
and normal kidney tissues. Compared with our previous investiga-
tion using RCC cell lines (Cho et al, 2000), hypomethylation of
each CpG was partial in RCC tissues. This may be explained by
contamination with DNAs from non-clear cell components or
surrounding non-cancerous tissues, although it cannot completely
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Figure 1 Bisulfite genomic sequences. CpG at – 74 bp of MN/CA9 was
completely methylated in a non-cancerous kidney tissue (K 1) and a RCC
(RCC 5), whereas partially hypomethylated in another RCC (RCC 10). 
Arrow shows CpG at – 74 bp
Figure 2 Differences of MN/CA9 promoter activities among 4 human RCC
cell lines. MN/CA9 promoter/luciferase reporter constructs were transfected
into MN/CA9 mRNA-positive cell lines (SK-RC-10 and SK-RC-44) and
MN/CA9 mRNA-negative cell lines (SK-RC-12 and SK-RC-14). MN/CA9
promoter activities in MN/CA9-negative cell lines were very low compared to
those in MN/CA9-positive cell lines
Table 2 Methylation status of MNCA9 promoter region in human RCC 
CpG site (bp) 
Sample –74 –19 –6 +4 +13 +40 
RCC 1 +/– ND + + + + 
RCC 2 +/– ND + + + + 
RCC 3 +/– ND + + + + 
RCC 4 +/– ND +/– +/– +/– + 
RCC 5 + ND + +  + + 
RCC 6 +/– ND + + + + 
RCC 7 + ND + +  + + 
RCC 8 +/– ND + + + + 
RCC 9 + ND + +  + + 
RCC 10 +/– ND +/– +/– +/– + 
RCC 11 + ND + +  + + 
RCC 12 +/– ND + +/– +/– + 
RCC 13 +/– ND + +/– +/– + 
K 1 + ND + + + + 
K 2 + ND + + + + 
K 3 + ND + + + + 
+: methylated; +/–: partially methylated (partially hypomethylated); 
K1, K2, K3: non-cancerous kidney tissues; ND: not determined. be denied that either of 2 alleles was hypomethylated in each cell
of RCC tissues. Nested PCR used in the genomic sequencing
protocol can make many copies from only a small amount of
contaminated DNA. Another difference between RCC cell lines
and RCC tissues is that hypomethylated CpGs in the MN/CA9
promoter region were clearly sparse in RCC tissues compared to
RCC cell lines. Maintenance of lines in cell culture may result in
wide hypomethylation in this region. 
The promoter activity of MN/CA9 was completely lost by methy-
lation of both whole and specific (GCGC) CpG sites of
promoter/reporter constructs. The MN/CA9 promoter (–158 to 
+ 42) contains only one GCGC sequence, corresponding to the CpG
at –74 bp. This finding, together with the strong correlation between
MN/CA9 expression and hypomethylation of the CpG at –74 bp in
RCC tissues, suggests that hypomethylation of the site of the
promoter may be needed to start transcription. It is well known that
expression of various tissue-specific genes is associated with
changes of the methylation status of their promoters (Busslinger 
et al, 1983; Lu and Davies, 1997; Kuramasu et al, 1998). Tumour
suppressor genes are often inactivated by methylation of promoters
in cancer tissues (Heman et al, 1994; Merlo et al, 1995; Yoshiura et
al, 1995), while some cancer-related genes are activated by
hypomethylation (Hanada et al, 1993; De Smet et al, 1996;
Nakayama et al, 1998). DNA binding of several transcription factors
whose recognition sequences contain a CpG is directly inhibited
when the CpG is methylated (Zingg and Jones, 1997). Since the
CpG at –74 bp is not located in a potential binding site for transcrip-
tion factors, methylation of this site may suppress transcription by a
putative methyl CpG-binding protein. Hypomethylation of onco-
genes or cancer-related genes in vivo has less frequently been
reported compared to hypermethylation of tumour suppressor genes.
Our present data demonstrate that hypomethylation is a practically
occurring and significant epigenetic change associated with gene
activation in RCC tissues. It is not unclear whether hypomethylation
of MN/CA9 is caused by genome-wide hypomethylation (De Smet
et al, 1996) or by gene-specific hypomethylation (Schmutte and
Janes, 1998). Elucidation of the process of MN/CA9 hypomethyla-
tion can result in discovery of other important genes contributing to
the development of clear cell RCCs.
The fact that promoter activities in MN/CA9-negative cell
lines were very low compared to those in MN/CA9-positive
cell lines indicates the existence of specific transcription factors
necessary for MN/CA9 activation. This is consistent with our
previous data. Although the expression was induced in MN/CA9-
negative RCC cell lines (SK-RC-12 and SK-RC-14) with the
demethylating agent, 5-aza-2′ -deoxycitidine, the levels were much
lower than in RCC cell lines with constitutive expression (Cho et
al, 2000). Other authors have reported interesting findings as to
MN/CA9 expression in malignancies. MN/CA9 was down-regu-
lated by wt VHL in a human RCC cell line with a VHL mutation
(Ivanov et al, 1998). In one recent investigation, the promoter
activity of MN/CA9 was suppressed by wt p53 in a human
mammary carcinoma cell line (Kaluzova et al, 2000). Other factors
such as VHL and p53 might be involved in MN/CA9 expression in
conjunction with promoter hypomethylation. 
In conclusion, MN/CA9 expression is strongly associated with
hypomethylation of the specific CpG site in the MN/CA9 promoter
region in RCC tissues. However, the activation mechanism of
MN/CA9 seems to be complicated and further investigation is
necessary. 
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Figure 3 Effect of CpG methylation on MN/CA9 promoter activity.
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